Actionable insights — Adding to LODE at $2.91
Not that he bought the dip, but the test he ran before he was allowed to — and how he kept a lottery-ticket bet from contaminating the core position.
How to read this page: a short intraday note supports only a couple of reusable methods — both about the discipline around averaging down, not about Comstock. The boxed line shows how each played out here. (Written source — no video timestamps.)
1. Before averaging down, run the "is there a reason?" search — and run it with other holders
The repeatable method
- When a position gaps down hard with no obvious catalyst, do not act on the price. First go looking for a fundamental cause: filings, financing news, permit or offtake changes, a downgrade, an index/ETF flow, a lock-up or warrant expiry.
- Do not run that search alone. Compare notes with other analysts who are themselves deeply invested in the name — people with the incentive to have already found the bad news if it exists, and the coverage depth to know where to look.
- Only if the search comes up empty on both counts do you get to call the move noise and add. An absence of evidence you actively hunted for is a different (and much stronger) thing than an absence of evidence you never looked for.
- Say the downside out loud in the same breath as the add, in scenario form rather than as a hedge: name the delivery milestone that has to land, and state where the price goes if it doesn't.
- Do not let a sum-of-the-parts number function as a floor. A paper asset value of 1.5–3x market cap is a reason the reward is asymmetric — it is not protection, because an un-delivered first-of-a-kind asset can be re-marked to nearly nothing.
Here: LODE sells off intraday; Mart and "other very smart and deeply invested analysts" find "nothing fundamental that warrants this," so he adds at $2.91 — while stating that SSOF's on-paper 1.5–3x market-cap value does not stop the stock "going a whole lot lower" if the first-of-a-kind facility doesn't deliver.
Watch for
- A drawdown where the news search comes up empty and other informed holders confirm the blank — versus one where you simply haven't found the reason yet.
- Single-asset, first-of-a-kind companies: assume "things can (and likely will) go wrong" as the base case, and size the add against the not-delivered scenario rather than the NAV.
2. Quarantine the speculative leg — separate message, separate money, separate expectation
The repeatable method
- When you want directional leverage on top of a conviction position, structure it as a distinct trade rather than by enlarging the equity stake — and communicate it separately, so a reader can take the core view without the lottery ticket.
- Size it as money you are "absolutely fine with potentially going to 0." That is the entry condition for the trade, not a disclaimer added afterwards.
- Pick the expiry off the thesis clock, not the calendar convenience: buy time past the catalyst you actually expect (here, a second half in which the company re-rates), so the bet isn't decided before the thesis has a chance to be.
- Keep the premium small in absolute terms — a cheap out-of-the-money call is a defined-loss instrument, so the maximum damage is knowable at entry and never forces a decision later.
- Track the two legs apart. The equity add is judged on the business over years; the option is judged on one date. Blending them is how a good long-term thesis gets marked as a failure by an expiry calendar.
Here: twelve minutes after the equity add, a deliberately "seperate message" flags Dec-18-2026 $5 calls bought at $0.20 — "a bet on the direction of the company being up again in the second half of the year. Again, very speculative."
Watch for
- Your own tendency to express extra conviction by enlarging an already-overweight equity position instead of by a defined-loss instrument.
- An option leg whose expiry sits before the milestone that is supposed to prove the thesis — that is a bet on the tape, not on the company.
Methods distilled from two Contrarian Codex Discord messages (linked above) for personal study. Not investment advice. © Contrarian Codex / "Mart" for source material.